Welcome to our dedicated page for Coherus news (Ticker: CHRS), a resource for investors and traders seeking the latest updates and insights on Coherus stock.
Coherus Oncology, Inc. (NASDAQ: CHRS) is a commercial-stage oncology company whose news flow is centered on its PD-1 inhibitor LOQTORZI (toripalimab-tpzi) and a proprietary immuno-oncology pipeline. Company announcements frequently highlight clinical data, regulatory developments, financial results and strategic updates related to its antibody-based cancer therapies.
News about Coherus Oncology often covers LOQTORZI in nasopharyngeal carcinoma (NPC), including long-term survival data from the JUPITER-02 Phase 3 trial evaluating LOQTORZI plus chemotherapy in recurrent or metastatic NPC. Releases also describe LOQTORZI’s approved indications in the United States and its role as the only FDA-approved and available treatment for recurrent, locally advanced or metastatic NPC across all patient subsets and lines of therapy.
Investors and clinicians following CHRS can expect regular updates on pipeline programs such as CHS-114 and casdozokitug. Coherus reports biomarker and proof-of-mechanism data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, in head and neck squamous cell carcinoma and other solid tumors, as well as clinical and translational findings for casdozokitug, a novel IL-27 antagonist in advanced solid tumors including hepatocellular carcinoma and non-small cell lung cancer.
The company’s news stream also includes quarterly financial results, business updates, participation in major healthcare and oncology conferences, and investor-focused events. These items provide context on revenue trends for LOQTORZI, research and development spending on its immuno-oncology programs, and corporate strategy.
For market participants tracking CHRS, the Coherus Oncology news page on Stock Titan aggregates these press releases and related coverage, offering a centralized view of clinical milestones, regulatory disclosures and financial communications that can influence perceptions of the company’s oncology franchise and pipeline progress.
Summary not available.
Summary not available.
Summary not available.
On April 27, 2023, Coherus BioSciences (Nasdaq: CHRS) and Junshi Biosciences announced that data from four pivotal clinical studies of toripalimab will be presented at the ASCO Annual Meeting from June 2-6, 2023. Key presentations include final overall survival analyses from phase 3 studies for nasopharyngeal carcinoma and non-small cell lung cancer, and interim analyses for resectable stage cancers. The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for advanced recurrent nasopharyngeal carcinoma. This demonstrates the potential of toripalimab, an anti-PD-1 monoclonal antibody, in treating multiple cancer types, with ongoing studies covering over 15 indications globally.
Coherus BioSciences reported Q4 2022 net product sales of $45.4 million and full-year sales of $211.0 million. The FDA plans an inspection of the toripalimab manufacturing site in Q2 2023, with launches of toripalimab and UDENYCA® products anticipated. The UDENYCA® autoinjector received FDA approval, while the on-body injector is under review. The company also plans a reduction in workforce by approximately 60 employees and expects combined R&D and SG&A expenses for 2023 to be $315 to $335 million, reflecting a nearly $100 million reduction from previous guidance. The net loss for Q4 2022 was $58.9 million.
Coherus BioSciences, Inc. (Nasdaq: CHRS) announced FDA approval for the UDENYCA® autoinjector, a pegfilgrastim treatment that reduces infection risks in cancer patients after chemotherapy. This innovative, easy-to-use device allows for both in-clinic and at-home administration, enhancing patient accessibility. The approval is supported by extensive data, and the autoinjector's commercial launch is planned for the second quarter of 2023. Additionally, a proprietary on-body injector is under FDA review, potentially expanding UDENYCA®'s market reach further. Over 263,000 patients have utilized UDENYCA® since its 2019 launch.
Coherus BioSciences (Nasdaq: CHRS) will present at two major investor conferences in March 2023. The first is the 43rd Annual Cowen Health Care Conference on March 7 at 2:10 p.m. ET, followed by the Barclays 2023 Global Healthcare Conference on March 14 at 4:05 p.m. ET. Audio webcasts of these presentations will be accessible on the Coherus investors' page and archived for 30 days. Investors are encouraged to connect to the webcasts promptly.
For inquiries, contact Marek Ciszewski, SVP Investor Relations at IR@coherus.com.
Coherus BioSciences, Inc. (CHRS) announced that it will release its fourth quarter and full year 2022 financial results on March 6, 2023, after market close. The company will host a conference call and webcast at 5:00 pm ET that same day to discuss the results and provide a business update. Interested parties can access the conference call by pre-registering for dial-in information. A replay of the webcast and press release will be available on Coherus' investor website after the call.
Coherus BioSciences (Nasdaq: CHRS) and Junshi Biosciences announced positive results from the final overall survival analysis of the JUPITER-02 trial.
The study evaluated the combination of toripalimab with chemotherapy in patients with advanced nasopharyngeal carcinoma (NPC), showing a statistically significant improvement in overall survival compared to chemotherapy alone.
The FDA has granted Breakthrough Therapy designation for toripalimab's use in this indication, underscoring its potential as a new standard-of-care treatment for NPC once approved.
Coherus BioSciences announced a significant milestone for its biosimilar CIMERLI®, as the Centers for Medicare and Medicaid Services assigned a Healthcare Common Procedure Coding System (HCPCS) Q-code effective April 1, 2023. This Q-code will enhance billing efficiency and reimbursement speed for healthcare providers. Paul Reider, Chief Commercial Officer, indicated that this development could catalyze market conversion and growth for CIMERLI® in 2023. CIMERLI® is the only FDA-approved interchangeable biosimilar of Lucentis®, indicated for various ocular diseases, making it a vital addition to Coherus' portfolio.
FAQ
What is the current stock price of Coherus (CHRS)?
What is the market cap of Coherus (CHRS)?
